Niramai uses thermal imaging plus AI to detect breast cancer non-invasively, especially for younger women. Cleared by India CDSCO and FDA-510(k). Backed by Mayo Clinic, BEENEXT, Dream Incubator. Bengaluru HQ.
Builder’s Brief
Niramai is a healthcare tool on Falcoscan. AI-powered breast cancer screening. Falcoscan rates Niramai with an Opportunity score of 72/100, a Saturation score of 8/100, and a Wrapper-risk score of 5/100. Market signal: stable. Niramai is founded in 2017, currently at Series_a stage. Pricing: Paid.
Market position · Healthcare
How Niramai compares in Healthcare
Niramai's opportunity score of 72 ranks #131 of 137 live Healthcare tools on Falcoscan, 9.8 points below the category average of 81.8. Its saturation score is 8/100, against a category average of 11. 75 of the 137 live Healthcare tools carry a hot signal, and Falcoscan has recorded 8 shutdowns in the category.
The top-rated live Healthcare tools on Falcoscan, other than Niramai, are DeepMind AlphaFold, Nuance DAX Copilot, Viz.ai AI Stroke Response, Tempus AI Diagnostics, and Viz.ai Stroke AI.
Is Niramai still operating?
Yes. Falcoscan's operating checks list Niramai as active.
Where is Niramai based?
Niramai is headquartered in Bengaluru, India.
Does Niramai have an API?
Falcoscan's records show no public API for Niramai.
Who is Niramai for?
Niramai is built for enterprises, hospitals, and healthcare providers.